Top Markets
Coin of the day
Novartis AG Novartis AG

Novartis AG

NOVN
Classificação em ações #57
Novartis AG researches, develops, manufactures, distributes, markets, and sells... Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Preço da ação
$149.90
Última sincronização: 2026-09-18
Valor de mercado
$284.92B
Variação (1 dia)
-0.66%
Variação (1 ano)
21.93%
País
CH
Negociar Novartis AG (NOVN)

Categoria

Histórico de preços das ações de Novartis AG (NOVN)
Preço de fecho mais alto: $155.10 em 2026-09-01

Preço de fecho mais baixo: $19.02 em 1995-04-01
Histórico de preços das ações da Novartis AG de 1995 a 2026
Desempenho anual do preço das ações
Ano Desempenho
2026 (TTM) 10.79%
2025 34.64%
2024 1.69%
2023 8.06%
2022 8.71%
2021 -8.14%
2020 -2.05%
2019 20.72%
2018 3.40%
2017 19.32%
2016 -17.48%
2015 -9.35%
2014 20.80%
2013 23.98%
2012 13.54%
2011 -2.30%
2010 4.11%
2009 15.79%
2008 -14.72%
2007 -4.76%
2006 10.95%
2005 6.32%
2004 13.45%
2003 19.37%
2002 4.81%
2001 -12.71%
2000 12.71%
1999 -56.75%
1998 15.24%
1997 58.59%
1996 48.26%
1995 0.00%
Preço das ações de empresas similares ou concorrentes
Empresa Preço da ação Variação 1a% País
$1.15K 53.22%
US
$269.75 53.10%
US
$263.75 18.56%
US
$474.96 36.76%
CH
$146.40 79.61%
US